tbuckley/cabot-search huggingface dataset:
Comparison of l-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma
Authors: Sied Kebir, Lazaros Lazaridis, Manuel Weber, Cornelius Deuschl, Ann-Kathrin Stoppek, Teresa Schmidt, Christoph Mönninghoff, Tobias Blau, Kathy Keyvani, Lale Umutlu, Daniela Pierscianek, Michael Forsting, Martin Stuschke, Gerald Antoch, Ulrich Sure, Christoph Kleinschnitz, Björn Scheffler, Patrick M. Colletti, Domenico Rubello, Ken Herrmann, Martin Glas
Journal: Clinical Nuclear Medicine (2019)

Amino acid PET and magnetic resonance spectroscopy (MRS) are at the forefront of noninvasive imaging techniques used for detection and subtyping of glioma-suspicious lesions. In this pilot study, we compare L-methyl-C-methionine PET and MRS for their ability to predict glioma subtypes.Nineteen patients with histologically, confirmed newly diagnosed glioma underwent preoperative L-methyl-C-methionine PET and MRS in 1 diagnostic session. According to the molecular portfolio and histopathologic diagnosis, patients were subdivided in isocitrate dehydrogenase (IDH) wild-type glioblastoma, IDH wild-type grade II/III glioma, IDH-mutant grade II/III glioma without 1p/19q codeletion, and with 1p/19q codeletion subgroups. Maximum tumor-to-brain ratio (TBRmax), creatine, choline, and N-acetyl aspartate peaks were correlated with postoperative histopathologic tumor diagnoses.Maximum tumor-to-brain ratio was highest in glioblastoma patients (4.18) followed by patients with IDH wild-type grade II and III glioma (3.41). The latter TBRmax values were higher compared with those in patients with IDH-mutant grade II/III glioma without 1p/19q codeletion (1.95) and in patients with IDH-mutant 1p/19q codeleted grade II and III glioma (2.79). Magnetic resonance spectroscopy marker distribution showed no clear trend. Receiver operating characteristic analysis revealed TBRmax to be the best performing parameter in identifying IDH status (area under the curve, 0.67) and all spectroscopy markers combined in identifying glioma subgroups (area under the curve, 0.68), respectively.L-Methyl-C-methionine PET and MRS bear limited potential in glioma subgrouping. L-Methyl-C-methionine PET appears to be superior in differentiating IDH status, whereas MRS is more helpful in glioma subgrouping.
The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach
Authors: Erik A. Jensen, Kevin Dysart, Marie G. Gantz, Scott McDonald, Nicolas A. Bamat, Martin Keszler, Haresh Kirpalani, Matthew M. Laughon, Brenda B. Poindexter, Andrea F. Duncan, Bradley A. Yoder, Eric C. Eichenwald, Sara B. DeMauro
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Current diagnostic criteria for bronchopulmonary dysplasia rely heavily on the level and duration of oxygen therapy, do not reflect contemporary neonatal care, and do not adequately predict childhood morbidity.
Inter‐rater and intrarater agreement and reliability in clinical staging of hidradenitis suppurativa/acne inversa
Authors: C.C. Zouboulis, Ł. Matusiak, G.B.E. Jemec, J.C. Szepietowski, P.J. Álvarez‐Chinchilla, A. Asoskova, H. Bonnekoh, G. Brattoli, T.S. Cetinarslan, J. Dawicka, V. Dente, Y. Gallyamova, G. Giovanardi, K. Glasenhardt, A.‐M. Ionescu, E. Janushaj, M.K. Lakhssassi, K.K. Lőrincz, D. Ludew, M. Makmatov‐Rys, M. Malickova, S.W. Mengesha, D. Mintoff, A. Otlewska, M. Papakou, A.M. Pirvan, L. Provvidenziale, F. Quadrana, N. Savickaja, G. Tamulyté, A. Trifu, A. Vīgante, K. Włodarek, V.A. Zouboulis
Journal: British Journal of Dermatology (2019)
PS-064-NAFLD simulator: An interactive open-access tool for long-term risks of NAFLD and NASH
Authors: Jagpreet Chhatwal, Ozden Onur Dalgic, Sumeyye Samur, Emily Bethea, Mary Ann Ladd, Tiannan Zhan, Kathleen Corey, Rohit Loomba
Journal: Journal of Hepatology (2019)
Abstract 19493: Sirt7 Contributes to Myocardial Tissue Repair by Maintaining TGF-β Signaling Pathway
Authors: Satoshi Araki, Yasuhiro Izumiya, Yuichi Kimura, Shinsuke Hanatani, Yoshiro Onoue, Satoru Yamamura, Thomas Braun, Eva Bober, Hisao Ogawa
Journal: Circulation (2015)

Background: Sirt7, one of the seven members of the mammalian sirtuin family, promotes oncogenic transformation. Tumor growth and metastasis require fibrotic and angiogenic responses. Here, we investigated the role of Sirt7 in cardiovascular tissue repair process. Methods and Results: In wild type (WT) mice, Sirt7 expression increased in response to acute cardiovascular injury, including myocardial infarction (MI) and hindlimb ischemia, particularly at the active wound healing site. Homozygous Sirt7 deficient (Sirt7-/-) mice showed susceptibility to cardiac rupture after MI, delayed blood flow recovery following hindlimb ischemia and impaired wound healing after skin injury, compared to WT mice. Histological analysis showed reduced fibrosis, fibroblast differentiation and inflammatory cell infiltration in the border zone of infarction in Sirt7-/- mice. In vitro, Sirt7-/- mice-derived or Sirt7 siRNA-treated cardiac fibroblasts showed reduced TGF-β signal activation and low expression levels of fibrosis-related genes compared with WT mice-derived or control siRNA-treated cells. These changes were accompanied by reduction in TGF-β receptor I (TβRI) protein. Loss of Sirt7 activated autophagy in cardiac fibroblasts. TβRI downregulation induced by loss of Sirt7 was blocked by autophagy inhibitor, and interaction of Sirt7 with protein interacting with protein kinase C, alpha (PICK1) was involved in this process. Conclusions: Sirt7 maintains TβRI by modulating autophagy and contributes to tissue repair processes.
THU-177-Interim results of an ongoing project to eliminate chronic hepatitis C in people who inject drugs with ongoing intravenous drug use and a high risk of non-adherence to direct-acting antivirals in Vienna
Authors: Caroline Schmidbauer, Angelika Schütz, Cornelia Schwanke, Raphael Schubert, Julian Luhn, Enisa Gutic, Roxana Pirker, Tobias Lang, Hans Haltmayer, Michael Gschwantler
Journal: Journal of Hepatology (2019)
On the shoulders of giants/shouldering the educational burden… your one-stop shoulder shop: Bern, 22 November 2019
Authors: Mario Bizzini, Nicolas Mathieu
Journal: British Journal of Sports Medicine (2019)

The Swiss Sports Physiotherapy Association (SSPA) will hold its 17th annual conference on 22nd November 2019 in Bern, capital of Switzerland and home of this event since 2005 (figure 1).



Figure 1 
Top shoulder conference, Bern, 22 November, 2019.



The goal of SSPA has always been to organise a high-quality scientific congress featuring international high-profile speakers. Our record-breaking 2015 conference—also the first World Congress of Sports Physical Therapy—focused on the ‘Return to Play Continuum’.1 For this year’s SSPA, we focus on…(check title of this piece…) yes, you guessed it! shoulder injuries with attention to diagnosis, treatment and advances in return to play advice. The shoulder—an amazing athletic weapon but also an Achilles heel one might say. …
THU-441-Site-specific structural N-glycan alterations limit CD73 nucleotidase activity in human hepatocellular carcinoma
Authors: Karel Alcedo, Andres Guerrero, Venkatesha Basrur, Monéa Richardson, Joshua McLane, Shanshan Wan, Chih-Chiang Tsou, Alexey Nesvizhskii, Theodore Welling, Carlito Lebrilla, Carol Otey, Hong Jin Kim, Bishr Omary, Natasha Snider
Journal: Journal of Hepatology (2019)
Primary care management of chest pain after coronary artery bypass surgery
Authors: Damian Gimpel, Raewyn Fisher, Zahoor Khan, David J McCormack
Journal: BMJ (2019)

### What you need to know

Coronary artery bypass grafting (CABG) is increasingly common and accounts for over half of all adult cardiac surgeries globally.1 Over 16 000 operations were performed in the UK in 2015.2 Recurrent or chronic chest pain after CABG can be extremely worrying for the patient and affect their quality of life.3 In a prospective cohort study (183 patients), a third of patients reported chronic chest pain on movement and 17% reported chest pain at rest at one year after CABG.4 This presents a diagnostic challenge in primary care and requires prompt investigation.5

This article presents a practical approach for non-specialists to evaluate chest pain in patients after a CABG with a median sternotomy (see box 1). We focus on chest pain in the medium to long term after surgery, when the patient has been discharged from postoperative services and is under the care of their general practitioner in the community. The approach can be relevant in patients with post-sternotomy chest pain after …
Utilization and clinical impact of genomic profiling for EGFR and ALK in non-squamous non-small cell lung cancer (NSCLC) in the community setting.
Authors: Martin Gutierrez, Harry D. Harper, Bohdan E. Halibey, Vincent A. Miller, Jerry Conway, Mark Oldroyd, Kelly Choi, Eric V Schultz, Andrew Pecora, Stuart L. Goldberg
Journal: Journal of Clinical Oncology (2015)

e19113 Background: Targeted therapies may increase survival in metastatic NSCLC. Thus, genomic profiling is recommended to aid treatment selection. Utilization & impact of testing in community (non-research) settings is underexplored. Methods: Retrospective review of pts with metastatic NSCLC, excluding squamous cell, treated by 69 physicians in Regional Cancer Care Associates (Jan 2011 - Dec 2014). Results: 722 pts with stage IV NSCLC were identified in the COTA (Cancer Outcome Tracking and Analysis) database (622 adenocarcinoma, 31 large cell, 69 NOS). 431 pts (60%) underwent some genomic profiling. 96 pts (22% of tested) harbored a mutation. EGFR mut were identified in 80 of 416 tested (19%); ALK rearrangements were identified in 17 of 355 tested (5%); one “double hit”. Among never/passive tobacco users the testing rate was 77% (103/134) with 40% (41/103) mut positive. Testing was performed on 267 of 453 (59%) former tobacco users with 34 (13%) harboring mut. Only 2 mut in 51 tested current smokers (n = 116). (testing rate p < 0.001, mut rate p < 0.001). Among oncologists treating > 10 pts testing rate was 60% (40-82%). 86% of EGFR mut and 67% ALK mut (with data available) received targeted therapy. 27 pts (4%) received empiric targeted therapy without documentation of a mutation. Median overall & 2-yr survival for the entire cohort was 14 mo & 38%. Overall survival for EGFR/ALK mut 44 mo, without mut 15 mo, 1 neg/1 untested 13 mo & both not tested 11 mo (4 way p < 0.0001, all 2 way p < 0.05). 2 yr survival rates for mut, unmutated, 1neg/1not test & both not tested: 61%, 40%, 30% and 31%. Conclusions: Genomic profiling for EGFR & ALK was underutilized in the community setting (60%; more common testing in non-smokers). Overall survival was improved among tested pts with actionable mutations. Universal testing would have resulted in projected 39 (5%) additional pts benefiting from targeted therapy. Given the utility of testing for only 2 markers sporadically, a prospective study utilizing Foundation One, a comprehensive genomic profile which can be performed on smaller specimens & characterizes all classes of genomic alterations across 100s of cancer related genes from a single specimen, is planned.
FRI-255-Dynamics of HCV epidemiology among HIV+ patients in Vienna
Authors: Caroline Schmidbauer, David Chromy, David Bauer, Victor Schmidbauer, Mattias Mandorfer, Armin Rieger, Florian Mayer, Heidemarie Holzmann, Michael Trauner, Michael Gschwantler, Thomas Reiberger
Journal: Journal of Hepatology (2019)
Phase II study of nimotuzumab and radiotherapy in children and adolescents with newly diagnosed diffuse intrinsic pontine gliomas (DIPG).
Authors: Sidnei Epelman, Vicente Odone, Ethel Gorender, Raphael Salles S. Medeiros, Ludmila Martins
Journal: Journal of Clinical Oncology (2015)

10061 Background: DIPG are amongst the most challenging tumors to treat in childhood with no drug proven to be effective. Standard of care remains focal radiotherapy alone however, rapid disease progression usually occurred. Median overall survival is less than 1 year, and the 2-year survival is less than 10%. Methods: Patients with clinically and radiologically confirmed, centrally reviewed newly diagnosed DIPG were eligible for this multicenter phase II study. The anti-epidermal growth factor receptor antibody, nimotuzumab (150 mg/m2) was administered intravenously once weekly concomitant with focal radiotherapy (54Gy) and every 2 weeks until tumor progression. Response evaluation was based on clinical and radiological assessments. Primary objective was to improve survival with a historic cohort that received radiation therapy alone. Results: 21 patients entered into this study (7/14, male/female; median age, 7.6 years; range 2-16 years). All received radiotherapy. Treatment was well tolerated. 40/502 cycles had adverse effects related to the drug and very mild. The majority of adverse effects were associated with progression of disease. Disease free survival at 7.3 months was 85.7% (CI95% - 70.7-100). Overall survival at 9 months was 71.4% and at one year, 57.1% (CI95% - 33.8-74) which demonstrated better results when compared with historic trials. Conclusions: This trial demonstrated some activity of nimotuzumab in DIPG. It was well tolerated and improved overall survival. A small subset of patients appeared to benefit from this anti-EGFR antibody and can be considered in future trials with synergistic drugs. An upfront biopsy can bring the prospect of a better understanding of DIPG biology and selection of better treatment. Clinical trial information: NTC01145170.
When pregnancy tames the wolf
Authors: Timothy B. Niewold, Shilpi Mehta-Lee
Journal: The Journal of Experimental Medicine (2019)

A state of relative immunosuppression exists in normal pregnancy. In this issue of JEM, Hong et al. (https://doi.org/10.1084/jem.20190185) perform blood immunomonitoring in pregnancy, in both healthy women and women with lupus, and observe early and sustained transcriptional modulation of lupus-related pathways in both groups. When signatures of inflammation did not normalize in lupus, risk of pregnancy complications was increased.
Assessment of the Data Sharing and Privacy Practices of Smartphone Apps for Depression and Smoking Cessation
Authors: Kit Huckvale, John Torous, Mark E. Larsen
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Inadequate privacy disclosures have repeatedly been identified by cross-sectional surveys of health applications (apps), including apps for mental health and behavior change. However, few studies have assessed directly the correspondence between privacy disclosures and how apps handle personal data. Understanding the scope of this discrepancy is particularly important in mental health, given enhanced privacy concerns relating to stigma and negative impacts of inadvertent disclosure. Because most health apps fall outside government regulation, up-to-date technical scrutiny is essential for informed decision making by consumers and health care professionals wishing to prescribe health apps. <h3>Objective</h3> To provide a contemporary assessment of the privacy practices of popular apps for depression and smoking cessation by critically evaluating privacy policy content and, specifically, comparing disclosures regarding third-party data transmission to actual behavior. <h3>Design and Setting</h3> Cross-sectional assessment of 36 top-ranked (by app store search result ordering in January 2018) apps for depression and smoking cessation for Android and iOS in the United States and Australia. Privacy policy content was evaluated with prespecified criteria. Technical assessment of encrypted and unencrypted data transmission was performed. Analysis took place between April and June 2018. <h3>Main Outcomes and Measures</h3> Correspondence between policies and transmission behavior observed by intercepting sent data. <h3>Results</h3> Twenty-five of 36 apps (69%) incorporated a privacy policy. Twenty-two of 25 apps with a policy (88%) provided information about primary uses of collected data, while only 16 (64%) described secondary uses. While 23 of 25 apps with a privacy policy (92%) stated in a policy that data would be transmitted to a third party, transmission was detected in 33 of all 36 apps (92%). Twenty-nine of 36 apps (81%) transmitted data for advertising and marketing purposes or analytics to just 2 commercial entities, Google and Facebook, but only 12 of 28 (43%) transmitting data to Google and 6 of 12 (50%) transmitting data to Facebook disclosed this. <h3>Conclusions and Relevance</h3> Data sharing with third parties that includes linkable identifiers is prevalent and focused on services provided by Google and Facebook. Despite this, most apps offer users no way to anticipate that data will be shared in this way. As a result, users are denied an informed choice about whether such sharing is acceptable to them. Privacy assessments that rely solely on disclosures made in policies, or are not regularly updated, are unlikely to uncover these evolving issues. This may limit their ability to offer effective guidance to consumers and health care professionals.
Prognostic factors of mortality after palliative procedures in patients ECOG 0-2 with malignant pleural effusion.
Authors: Fernando Abrao, Igor Abreu, Mariana Campello, Geisa Garcia, Renata D'Alpino D'Alpino, Riad N. Younes
Journal: Journal of Clinical Oncology (2015)

e20653 Background: The aim of this study was to identify predictors of overall survival (OS) in patients with malignant pleural effusion (MPE) who underwent pleural palliative procedures. Methods: Data was retrospectively collected from our prospective database between January 2013 and July 2014 on 64 patients with MPE and complete follow-up thirty days after the procedure. OS was calculated by the Kaplan-Meier method. Significant factors in the univariate analysis entered a Cox multivariate analysis. Results: A total of 64 patients (20 males) were included in the analysis. Median age was 60 (range 24-86). Procedures included pleurodesis by intercostal drain (n = 16), thoracoscopic pleurodesis (n = 17) and drainages (n = 31). Primary tumors included lung (n = 18), breast (n = 26), gastrointestinal (n = 5), and others (n = 15). Median follow-up time for surviving patients was 263 days. Median OS for the entire cohort was not reached yet. In univarate analysis, gastrointestinal primary tumor site (p = 0.001), American Society of Anesthesiologists (ASA) physical status classification of 3 versus 1/2 (p = 0.034), ECOG 2 versus 0/1 (p = 0.04), serum albumin < 2.5 mg/dL (p = 0.006), protein < 3.6 mg/dL (p = 0.024), and neutrophil/lymphocyte ratio (NLR) > 5 (p = 0.040) were associated with a significantly reduced OS. OS was not significantly different for gender, age, type of procedure, body mass index, lactate dehydrogenase (LDH), pleural glucose, pH, citologia, levels of adenosine deaminase (ADA) and volume. In multivariate analysis, gastrointestinal primary site (p = 0.006), low albumin (p = 0.017), and high NLR (p = 0.007) maintained significance. Conclusions: In our cohort of patients with MPE who underwent pleural palliative procedures, gastrointestinal malignancy, hypoalbuminemia and high NLR were significantly associated with shorter OS. The identification of those prognostic factors may assist the choice of palliative technique.
Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1
Authors: Shiming Peng, Wen Xiao, Dapeng Ju, Baofa Sun, Nannan Hou, Qianlan Liu, Yanli Wang, Haijiao Zhao, Chunchun Gao, Song Zhang, Ran Cao, Pengfei Li, Huanwei Huang, Yongfen Ma, Yankai Wang, Weiyi Lai, Zhixiong Ma, Wei Zhang, Song Huang, Hailin Wang, Zhiyuan Zhang, Liping Zhao, Tao Cai, Yong-Liang Zhao, Fengchao Wang, Yongzhan Nie, Gang Zhi, Yun-Gui Yang, Eric Erquan Zhang, Niu Huang
Journal: Science Translational Medicine (2019)

Recent studies have established the involvement of the fat mass and obesity-associated gene (FTO) in metabolic disorders such as obesity and diabetes. However, the precise molecular mechanism by which FTO regulates metabolism remains unknown. Here, we used a structure-based virtual screening of U.S. Food and Drug Administration-approved drugs to identify entacapone as a potential FTO inhibitor. Using structural and biochemical studies, we showed that entacapone directly bound to FTO and inhibited FTO activity in vitro. Furthermore, entacapone administration reduced body weight and lowered fasting blood glucose concentrations in diet-induced obese mice. We identified the transcription factor forkhead box protein O1 (FOXO1) mRNA as a direct substrate of FTO, and demonstrated that entacapone elicited its effects on gluconeogenesis in the liver and thermogenesis in adipose tissues in mice by acting on an FTO-FOXO1 regulatory axis.
PS-008-E2F2 mediated repression of fatty acid B-oxidation is mitigated through CREB1 in progressive non-alcoholic fatty liver disease
Authors: Francisco Gonzalez-Romero, Daniela Mestre, Igor Aurrekoetxea, Diego Sáenz de Urturi, Beatriz Gomez-Santos, Maitane Nuñez-García, Xabier Buqué, Igotz Delgado, Marta Palomo-Irigoyen, Miguel Tamayo-Caro, Ashwin Woodhoo, Marta Varela-Rey, María Luz Martínez-Chantar, Ainhoa Iglesias, Richard Lee, Sanjay Bhanot, Ana Zubiaga, Patricia Aspichueta
Journal: Journal of Hepatology (2019)
SAT-167-Hepatitis-E-genome sequencing via capture-probe targeting and NGS allows characterisation of viral variability
Authors: Swantje Gundlach, Alexandra Leß, Jiabin Huang, Daniela Indenbirken, Christine Dahlke, Sven Pischke, Marc Lütgehetmann, Marylyn M. Addo, Nicole Fischer
Journal: Journal of Hepatology (2019)
David Ivor Keith Evans
Authors: Alison Howarth
Journal: BMJ (2019)

David Ivor Keith Evans was awarded a Saunders scholarship to read classics at Downing College, Cambridge, in 1951. He went on to study medicine at St Thomas’ Hospital Medical School. He met his future wife, Brenda, while they were working as junior doctors in Carshalton. They moved to Manchester with their young family in 1965, where he worked briefly as senior registrar in pathology (haematology) before being appointed consultant haematologist at Monsall Hospital (1966-1987), and the Royal Manchester and Booth Hall children’s hospitals (1966-1992). He was honorary lecturer in child health at the University of Manchester (1970-1992), with nearly 100 articles to his name.

David was a medical pioneer who dedicated his career to setting up and running …
FRI-046-Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test
Authors: Carla Fiorella Murillo Perez, Aliya Gulamhusein, Marco Carbone, Palak Trivedi, Adriaan Van der Meer, Christophe Corpechot, Pier Maria Battezzati, Willem J Lammers, Annarosa Floreani, Albert Parés, Henk Van Buuren, Frederik Nevens, Marlyn J. Mayo, Kris V. Kowdley, Cyriel Ponsioen, George Dalekos, Douglas Thorburn, Andrew L. Mason, Nikolaos Gatselis, Verhelst Xavier, Tony Bruns, Harry Janssen, Keith D. Lindor, Olivier Chazouillères, Pietro Invernizzi, Bettina Hansen, Gideon Hirschfield
Journal: Journal of Hepatology (2019)
SAT-161-Prevalence of HBV and syphilis co-infection in Ulaanbaatar population, Mongolia
Authors: Delgerbat Boldbaatar, Uurtsaikh Baatarsuren, Purevjargal Bat-Ulzii, Oyungerel Lkhagva-Ochir, Zolzaya Davaadorj, Byambasuren Ochirsum, Maral Myanganbayar, Khatantuul Boldbaatar, Zulkhuu Genden, Dahgwahdorj Yagaanbuyant, Altankhuu Murdorj, Andreas Bungert, Naranbaatar Dashdorj, Naranjargal Dashdorj
Journal: Journal of Hepatology (2019)
SAT-428-Prediction of liver stiffness by serum indexes in HCV-infected patients with or without HIV coinfection
Authors: Nicolas Merchante, Álvaro Mena de Cea, Juan Manuel Pascasio, Andrés Marco, Manuel Rodríguez, Miguel Angel Simón, Manuel Hernández Guerra, Ángeles Castro, Álvaro Giráldez, Elisabet Turu, Carmen A. Navas, Jessica Montero, Dalia Elena Morales, Juan Macias Sanchez
Journal: Journal of Hepatology (2019)